サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：心房細動の世界市場-2023年～2030年
市場調査レポート
商品コード
1297802

心房細動の世界市場-2023年～2030年

Global Atrial Fibrillation Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
心房細動の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

心房細動の世界市場は、2022年に193億米ドルに達し、2030年には428億米ドルに達することで有利な成長を示すと予測されています。心房細動の世界市場は、2023年から2030年の予測期間中に10.7%のCAGRを示すと予測されています。

心房細動（A-fib）は、心臓に血栓を生じさせる不整脈（不規則で通常非常に速い心臓のリズム）です。脳卒中、心不全、その他の心臓関連の問題はすべて心房細動によって増加します。

心房細動の間、心臓の一番上の部屋（心房）は、一番下の部屋（心室）とリズムがずれて、無秩序に不規則に拍動します。心房細動の多くの人は自覚症状がないです。心房細動は、逆に、鼓動が激しくなるような心拍（動悸）、息切れ、脱力感を引き起こすことがあります。

市場力学

肥満と心臓病の負担増が市場成長を牽引

心房細動市場は、世界中で肥満と心臓病の有病率が上昇していることが市場を牽引しています。さらに、心臓病は世界中で死亡の主な原因の1つであり、ライフスタイルの変化により、心臓病を患う人の数が急増しています。肥満は心血管疾患（CVD）、特に心不全（HF）や冠動脈性心疾患（CHD）の発症リスクの上昇と関連しています。

肥満がCVDリスクを高めるメカニズムには、血行動態に影響を与え、心臓の構造を変化させる体組成の変化が関与しています。脂肪組織から産生される炎症性サイトカインは心機能障害を誘発し、動脈硬化性プラークの形成を促進します。

心房細動を効果的に治療する戦略の欠如

心房細動の病態に関する十分な知識がないこと、また抗不整脈薬治療に伴う効率の悪さと副作用が、心房細動の治療に大きな障害となっています。

心房細動の患者数が拡大し、抗凝固薬、抗不整脈薬、心拍コントロール薬などの治療法を適応する必要性が高まっていることは、通常の医療システムの負担を増大させています。さらに、心房細動や潜在的な治療技術に関する認識や理解の不足が、心房細動治療機器や手技の普及を遅らせています。

COVID-19の影響分析

COVID-19が心房細動に与えた影響は甚大でした。包括的な研究によると、心房細動の発生率はCOVID-19患者の8％であり、高齢、男性、高血圧と関連していました。心房細動のある患者は心房細動のない患者よりも全死亡のリスクが高かったです。同様の結果は新たに心房細動と診断された患者でもみられました。

この所見は、COVID-19患者における心房細動の悪影響を強調し、心房細動を合併しているCOVID-19患者の予防、診断、治療のための独自の的を絞った対策を開発する必要性を支持するものです。これらの患者をモニターする最良の方法，特に抗血栓療法を決定するためには，さらなる調査が必要です。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響を与える要因
    • 促進要因
      • 開発された治療法の増加
    • 抑制要因
      • 心房細動を効果的に治療する戦略の欠如
    • 機会
      • 技術の開発
    • 影響分析

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19の分析

第7章 治療タイプ別

  • 非薬物療法
  • 無線周波数ベース
  • HIFUベース
  • 冷凍アブレーションベース
  • その他
  • 薬物治療

第8章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東とアフリカ

第9章 競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第10章 企業プロファイル

  • AtriCure
  • Biosense Webster
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • Cardio Focus
  • Endoscopic Technologies
  • Sanofi Aventis
  • Abbott
  • Johnson and Johnson

第11章 付録

目次
Product Code: PH446

Market Overview

The Global Atrial Fibrillation Market reached US$ 19.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 42.8 billion by 2030. The Global Atrial Fibrillation Market is expected to exhibit a CAGR of 10.7% during the forecast period 2023-2030.

Atrial fibrillation (A-fib) is an arrhythmia (an irregular and typically very fast heart rhythm) that can result in blood clots in the heart. Stroke, heart failure, and other heart-related problems are all increased by atrial fibrillation.

During atrial fibrillation, the heart's top chambers (the atria) beat chaotically and irregularly, out of rhythm with the bottom chambers (the ventricles). Many persons with atrial fibrillation have no symptoms. Atrial fibrillation, conversely, can induce a rapid, hammering heartbeat (palpitations), shortness of breath, or weakness.

Market Dynamics

The Rising Burden of Obesity and Heart Diseases Drives the Market Growth

The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality around the world, and due to the changing lifestyle, the number of people suffering from heart diseases is proliferating. Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD).

The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue can induce cardiac dysfunction and promote the formation of atherosclerotic plaques.

Lack of Strategies to Effectively Treat Atrial Fibrillation

The absence of a thorough knowledge of the pathogenesis of atrial fibrillation, as well as the inefficiency and adverse effects associated with antiarrhythmic medication therapy, pose significant obstacles in treating atrial fibrillation.

The expanding number of patients with atrial fibrillation and the growing need to adapt treatment options such as anticoagulation, antiarrhythmic medicines, and rate control medications is increasing the normal health care system load. Furthermore, a lack of awareness and understanding concerning atrial fibrillation and potential therapeutic techniques is slowing the uptake of atrial fibrillation therapy devices and procedures.

COVID-19 Impact Analysis

The influence of COVID-19 on atrial fibrillation was enormous; according to a comprehensive study, the incidence of atrial fibrillation was 8% of COVID-19 patients and was related to older age, male sex, and hypertension. Patients with Atrial Fibrillation had a greater risk of all-cause death than those who did not have atrial fibrillation. Similar results were seen in patients with newly diagnosed atrial fibrillation.

The findings highlight the negative effect of atrial fibrillation in COVID-19 patients and support the necessity for developing unique and targeted measures for the prevention, diagnosis, and therapy of COVID-19 patients with concurrent AF. More research is needed to determine the best ways to monitor these individuals, particularly antithrombotic treatments.

Segment Analysis

The Global Atrial Fibrillation Market is segmented based on treatment type and end user.

The Ambulatory Surgical Center Segment is Expected to Grow During the Forecast Period

The ambulatory surgical center segment is expected to witness good growth of around 33.3% due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure are expected to propel the market.

However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, encourage patients to opt for minimally invasive surgeries, which is expected to boost market growth.

Geographical Analysis

North America is the dominating region during the forecast period.

The North American region is expected to dominate the atrial fibrillation market and account for around 41.5% in the forecast period. This is majorly attributed to the rising patient pool in the region and the presence of key players.

The North American region is predicted to lead the worldwide atrial fibrillation market due to the growing acceptance of technologically sophisticated devices and a significant increase in cardiac problems among the aging and general population.

Furthermore, a well-established healthcare infrastructure is projected to support the market's long-term expansion in North America. During the projection period, the North American atrial fibrillation market benefit from patient's high disposable income and growing fibrillation prevalence.

Competitive Landscape

The major global players include: AtriCure, Biosense Webster, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, Cardio Focus, Endoscopic Technologies, Sanofi Aventis, Abbott, Johnson and Johnson.

Why Purchase the Report?

  • To visualize the Global Atrial Fibrillation Market segmentation based on the treatment type, end user and region, and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous atrial fibrillation market level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Atrial Fibrillation Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1 Snippet by Treatment Type
  • 3.2 Snippet by End User
  • 3.3 Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1 Increase in Developed Treatments
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Strategies to Effectively Treat Atrial Fibrillation
    • 4.1.3. Opportunity
      • 4.1.3.1. Development of Technology
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • Non-Pharmacological Treatment

Maze Surgery

Catheter Ablation

  • Radiofrequency Based
  • HIFU Based
  • Cryoablation Based
  • Others

Electric Cardioversion

  • Pharmacological Treatment

Anti-arrhythmic Drugs

Anti-coagulant Drugs

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. The U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. The UK
      • 8.3.5.3. France
      • 8.3.5.4. Italy
      • 8.3.5.5. Spain
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. Australia
      • 8.5.5.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9. Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

  • 11.1. AtriCure
  • 11.2. Biosense Webster
  • 11.3. Boehringer Ingelheim GmbH
  • 11.4. Boston Scientific Corporation
  • 11.5. Bristol-Myers Squibb Corporation
  • 11.6. Cardio Focus
  • 11.7. Endoscopic Technologies
  • 11.8. Sanofi Aventis
  • 11.9. Abbott
  • 11.10. Johnson and Johnson

LIST NOT EXHAUSTIVE

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us